Presence of C-type natriuretic peptide in human kidney and urine

Michael T. Mattingly, Roland R. Brandt, Denise M. Heublein, Chi Ming Wei, Amiram Nir, John C Jr. Burnett

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The current study was undertaken to investigate the presence of CNP immunoreactivity in both human kidney and urine. Immunohistochemical staining with an indirect immunoperoxidase method utilizing an antibody which is 100% cross-reactive to both CNP-53 and CNP-22 was performed on five human kidney specimens (three biopsies of normal cadaveric donor kidneys and two of normal autopsy specimens). CNP immunoreactivity was positive in proximal, distal and medullary collecting duct tubular cells in a cytoplasmic and granular staining pattern. CNP immunoreactivity was also determined in the urine of five healthy volunteers utilizing a sensitive and specific double-antibody radioimmunoassay with a mean concentration of 10.8 ± 1.0 pg/ml. With the utilization of high pressure liquid chromatography, this immunoreactivity proved to be consistent with bath the low molecular weight form, CNP-22, as well as the high molecular weight form, CNP-53. Urinary excretion of CNP was also measured in normal subjects (N = 5) and in patients with congestive heart failure (CHF, N = 6). CHF patients excreted over three times more CNP than normals (27.2 ± 2.8 vs. 8.7 ± 0.81 pg/min, P < 0.004) despite no difference between the two groups in plasma CNP concentrations (6.97 ± 0.28 vs. 8.08 ± 1.52 pg/ml, P = NS). This study demonstrates for the first time the presence of CNP immunoreactivity in human kidney and suggests that renal tubular cells may be an additional non-vascular site of synthesis for this cardiorenal acting peptide. This study also demonstrates an increase in urinary CNP excretion in congestive heart failure.

Original languageEnglish (US)
Pages (from-to)744-747
Number of pages4
JournalKidney International
Volume46
Issue number3
StatePublished - Sep 1994

Fingerprint

C-Type Natriuretic Peptide
Urine
Kidney
Heart Failure
Molecular Weight
Staining and Labeling
Antibodies
Baths
Radioimmunoassay
Autopsy
Healthy Volunteers
High Pressure Liquid Chromatography
Tissue Donors
Biopsy
Peptides

ASJC Scopus subject areas

  • Nephrology

Cite this

Mattingly, M. T., Brandt, R. R., Heublein, D. M., Wei, C. M., Nir, A., & Burnett, J. C. J. (1994). Presence of C-type natriuretic peptide in human kidney and urine. Kidney International, 46(3), 744-747.

Presence of C-type natriuretic peptide in human kidney and urine. / Mattingly, Michael T.; Brandt, Roland R.; Heublein, Denise M.; Wei, Chi Ming; Nir, Amiram; Burnett, John C Jr.

In: Kidney International, Vol. 46, No. 3, 09.1994, p. 744-747.

Research output: Contribution to journalArticle

Mattingly, MT, Brandt, RR, Heublein, DM, Wei, CM, Nir, A & Burnett, JCJ 1994, 'Presence of C-type natriuretic peptide in human kidney and urine', Kidney International, vol. 46, no. 3, pp. 744-747.
Mattingly MT, Brandt RR, Heublein DM, Wei CM, Nir A, Burnett JCJ. Presence of C-type natriuretic peptide in human kidney and urine. Kidney International. 1994 Sep;46(3):744-747.
Mattingly, Michael T. ; Brandt, Roland R. ; Heublein, Denise M. ; Wei, Chi Ming ; Nir, Amiram ; Burnett, John C Jr. / Presence of C-type natriuretic peptide in human kidney and urine. In: Kidney International. 1994 ; Vol. 46, No. 3. pp. 744-747.
@article{4c011bb96a1642109fa5dc51d3e37014,
title = "Presence of C-type natriuretic peptide in human kidney and urine",
abstract = "The current study was undertaken to investigate the presence of CNP immunoreactivity in both human kidney and urine. Immunohistochemical staining with an indirect immunoperoxidase method utilizing an antibody which is 100{\%} cross-reactive to both CNP-53 and CNP-22 was performed on five human kidney specimens (three biopsies of normal cadaveric donor kidneys and two of normal autopsy specimens). CNP immunoreactivity was positive in proximal, distal and medullary collecting duct tubular cells in a cytoplasmic and granular staining pattern. CNP immunoreactivity was also determined in the urine of five healthy volunteers utilizing a sensitive and specific double-antibody radioimmunoassay with a mean concentration of 10.8 ± 1.0 pg/ml. With the utilization of high pressure liquid chromatography, this immunoreactivity proved to be consistent with bath the low molecular weight form, CNP-22, as well as the high molecular weight form, CNP-53. Urinary excretion of CNP was also measured in normal subjects (N = 5) and in patients with congestive heart failure (CHF, N = 6). CHF patients excreted over three times more CNP than normals (27.2 ± 2.8 vs. 8.7 ± 0.81 pg/min, P < 0.004) despite no difference between the two groups in plasma CNP concentrations (6.97 ± 0.28 vs. 8.08 ± 1.52 pg/ml, P = NS). This study demonstrates for the first time the presence of CNP immunoreactivity in human kidney and suggests that renal tubular cells may be an additional non-vascular site of synthesis for this cardiorenal acting peptide. This study also demonstrates an increase in urinary CNP excretion in congestive heart failure.",
author = "Mattingly, {Michael T.} and Brandt, {Roland R.} and Heublein, {Denise M.} and Wei, {Chi Ming} and Amiram Nir and Burnett, {John C Jr.}",
year = "1994",
month = "9",
language = "English (US)",
volume = "46",
pages = "744--747",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Presence of C-type natriuretic peptide in human kidney and urine

AU - Mattingly, Michael T.

AU - Brandt, Roland R.

AU - Heublein, Denise M.

AU - Wei, Chi Ming

AU - Nir, Amiram

AU - Burnett, John C Jr.

PY - 1994/9

Y1 - 1994/9

N2 - The current study was undertaken to investigate the presence of CNP immunoreactivity in both human kidney and urine. Immunohistochemical staining with an indirect immunoperoxidase method utilizing an antibody which is 100% cross-reactive to both CNP-53 and CNP-22 was performed on five human kidney specimens (three biopsies of normal cadaveric donor kidneys and two of normal autopsy specimens). CNP immunoreactivity was positive in proximal, distal and medullary collecting duct tubular cells in a cytoplasmic and granular staining pattern. CNP immunoreactivity was also determined in the urine of five healthy volunteers utilizing a sensitive and specific double-antibody radioimmunoassay with a mean concentration of 10.8 ± 1.0 pg/ml. With the utilization of high pressure liquid chromatography, this immunoreactivity proved to be consistent with bath the low molecular weight form, CNP-22, as well as the high molecular weight form, CNP-53. Urinary excretion of CNP was also measured in normal subjects (N = 5) and in patients with congestive heart failure (CHF, N = 6). CHF patients excreted over three times more CNP than normals (27.2 ± 2.8 vs. 8.7 ± 0.81 pg/min, P < 0.004) despite no difference between the two groups in plasma CNP concentrations (6.97 ± 0.28 vs. 8.08 ± 1.52 pg/ml, P = NS). This study demonstrates for the first time the presence of CNP immunoreactivity in human kidney and suggests that renal tubular cells may be an additional non-vascular site of synthesis for this cardiorenal acting peptide. This study also demonstrates an increase in urinary CNP excretion in congestive heart failure.

AB - The current study was undertaken to investigate the presence of CNP immunoreactivity in both human kidney and urine. Immunohistochemical staining with an indirect immunoperoxidase method utilizing an antibody which is 100% cross-reactive to both CNP-53 and CNP-22 was performed on five human kidney specimens (three biopsies of normal cadaveric donor kidneys and two of normal autopsy specimens). CNP immunoreactivity was positive in proximal, distal and medullary collecting duct tubular cells in a cytoplasmic and granular staining pattern. CNP immunoreactivity was also determined in the urine of five healthy volunteers utilizing a sensitive and specific double-antibody radioimmunoassay with a mean concentration of 10.8 ± 1.0 pg/ml. With the utilization of high pressure liquid chromatography, this immunoreactivity proved to be consistent with bath the low molecular weight form, CNP-22, as well as the high molecular weight form, CNP-53. Urinary excretion of CNP was also measured in normal subjects (N = 5) and in patients with congestive heart failure (CHF, N = 6). CHF patients excreted over three times more CNP than normals (27.2 ± 2.8 vs. 8.7 ± 0.81 pg/min, P < 0.004) despite no difference between the two groups in plasma CNP concentrations (6.97 ± 0.28 vs. 8.08 ± 1.52 pg/ml, P = NS). This study demonstrates for the first time the presence of CNP immunoreactivity in human kidney and suggests that renal tubular cells may be an additional non-vascular site of synthesis for this cardiorenal acting peptide. This study also demonstrates an increase in urinary CNP excretion in congestive heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0028128417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028128417&partnerID=8YFLogxK

M3 - Article

C2 - 7996796

AN - SCOPUS:0028128417

VL - 46

SP - 744

EP - 747

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -